Just Prior to Leadership Change, FDA Announces Public Workshops to Advance Dialogues on HCT Product Development and Optimizing Pregnancy Registries

January 21, 2025

Reading Time : 2 min

In the final stretch of the Biden administration, the Food and Drug Administration (FDA) laid the groundwork for continued engagement with the public on two challenging areas of product development, each of which is of high interest to patients, clinical communities, industry stakeholders and policy-makers in Congress.

The FDA is pressing forward on supporting human cell therapies and tissue-based product development. On January 17, 2025, the FDA issued a notice in the Federal Register announcing a virtual public workshop entitled “Cell Therapies and Tissue-Based Products: A Public Workshop on Generating Scientific Evidence to Facilitate Development” to fulfill Section 3205 of the Food and Drug Omnibus Reform Act of 2022 (P.L. 117-328), which required the FDA to hold a public workshop to discuss the best practices on generating scientific data necessary to further facilitate the development of certain human cell-, tissue- and cellular-based medical products (HCT/P).

The FDA’s HCT/P workshop is scheduled to be held on February 25, 2025, and topics to be discussed during the workshop include (1) the current state of the science for tissue and cell-derived therapies and explore what challenges remain as the field continues to mature; (2) nonclinical work to assess the safety of cell therapy products in support of product development; (3) considerations for characterization of cell therapy products to help ensure manufacturing quality during product development and through commercialization; (4) clinical considerations and future directions for locally administered cell therapies under investigation for niche indications; and (5) considerations for a revised risk-based HCT/P framework. The deadline for submitting comments on this workshop is March 18, 2025.

In addition, by announcing a public workshop on optimizing pregnancy registries, the FDA is focusing on another challenging areas of product development while also pursuing a Prescription Drug User Fee Act (PDUFA) commitment. In the most recent reauthorization of PDUFA commitment letter, the FDA agreed to develop a framework describing how to use data optimally from different types of post-approval pregnancy safety studies. On January 17, 2025, the FDA issued a notice announcing a public workshop entitled “Optimizing Pregnancy Registries” to be held on March 27 and 28. This public workshop is being held in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation program.

The purpose of the public workshop is to discuss challenges in designing and implementing pregnancy registries and consider innovative approaches to improve the design and conduct of pregnancy registries. In announcing the workshop, the FDA announced the it will discuss the current status of pregnancy registries and challenges in gathering data regarding the safety of drug and biological products used during pregnancy, perspectives from interested parties (FDA, academia, industry, health care providers and patients) on strategies to improve the design and conduct of pregnancy registries, and innovative approaches/models to facilitate the conduct of pregnancy registries, including disease-based multi-product, multi-sponsor pregnancy registries.

Both of these public workshops provide opportunities for stakeholders to engage with the FDA on areas of product development for patients and also demonstrate how the agency’s perpetual work on behalf of patients and public health spans administrations.

Share This Insight

Previous Entries

Eye on FDA

September 24, 2025

On Tuesday, September 23, 2025, FDA published guidance titled “Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency.” The guidance, a draft of which was published on May 6, 2024, specifies the factors that FDA intends to assess in deciding whether to issue an enforcement discretion policy with regard to in vitro diagnostics (IVD) manufacturers offering unapproved IVDs, among other devices, during a declared emergency. These factors include:

...

Read More

Eye on FDA

September 23, 2025

Last week, the U.S. Food and Drug Administration (FDA) issued a proposed rule to revoke the color additive listing for Orange B, a synthetic dye historically used on the casings and surfaces of frankfurters and sausages. This action is part of the broader “Make America Healthy Again” (MAHA) initiative to phase out petroleum-based foods from the American food supply by the end of 2026 and efforts to modernize the agency’s regulations.

...

Read More

Eye on FDA

September 12, 2025

The White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., released its highly anticipated strategy outlining a multi-agency approach focused on addressing childhood chronic disease. The strategy builds on the Commission’s inaugural health assessment, a report which examined the rising rates of childhood chronic diseases in the country and identified four primary drivers: poor diet due to consumption of ultra-processed foods (UPFs), exposure to environmental chemicals; increased technological use; and overmedicalization. To combat these challenges, the strategy released on September 9, 2025, outlines a four-prong approach which provides further insight into the areas the administration sees as key areas of MAHA going forward: advancing research, realigning incentives, increasing public awareness and fostering private sector collaborations.

...

Read More

Eye on FDA

September 8, 2025

On September 3, 2025, the Food and Drug Administration (FDA) announced Rare Disease Evidence Principles (RDEP) with processes aimed at providing greater predictability and facilitating the development and review of drugs intended to treat rare diseases with very small patient populations and significant unmet medical needs driven by a known genetic defect. In conjunction with the agency’s announcement of the new processes jointly proposed by the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the agency also unveiled additional information regarding eligibility and the potential for post-marketing requirements for those sponsors who participate in it.

...

Read More

Eye on FDA

August 27, 2025

Food dye reform has been an area of focus for the Trump administration as part of its Make America Healthy Again (MAHA) initiative, giving momentum to an effort the Food and Drug Administration (FDA) had already started by banning Red No. 3 for use in food and ingested drugs. FDA has continued to prioritize this work by taking actions to phase out the use of synthetic dyes and move to natural dyes since calling for these changes earlier this year, as discussed in our previous blog on the related announcement by the administration.

...

Read More

Eye on FDA

August 12, 2025

Last week, former Food and Drug Administration (FDA) Commissioner David Kessler submitted a citizen petition urging FDA to revoke the generally recognized as safe (GRAS) status of refined carbohydrates used in industrial food processing. The petition follows FDA’s and the United States Department of Agriculture’s (USDA) joint request for information (RFI) to establish a formal definition for ultra-processed foods (UPFs) and offers FDA a legal pathway to change the regulatory status of these ingredients.

...

Read More

Eye on FDA

August 6, 2025

On August 6, 2025, the U.S. Food and Drug Administration (FDA) became the latest governmental agency to confirm that fluoropolymers are both safe and necessary. After an independent safety review of fluoropolymers in medical devices showed no conclusive evidence of health issues, FDA concluded that fluoropolymers are “very unlikely to cause toxicity” because of molecular size and further that they are essential for medical devices to function. As a result, “FDA’s evaluation is that currently there is no reason to restrict their continued use in devices.” This announcement will be a source of relief to the device and diagnostics industries.

...

Read More

Eye on FDA

July 25, 2025

On July 25, the U.S. Food and Drug Administration (FDA), in collaboration with the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture (USDA), unveiled the highly anticipated joint request for information on ultra-processed foods (UPFs). Specifically, the administration is seeking information and data to help develop a uniform definition for UPFs in the U.S. food supply.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.